Efficacy and Safety of a Sore Throat Lozenge Containing Lidocaine and Cetylpyridinium Chloride in Patients With Sore Throat Due to a Common Cold.
Launched by NOVARTIS · Dec 22, 2010
Trial Information
Current as of October 11, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with sore throat due to an upper respiratory tract infection, with recent onset (within 48 hours)
- • Sore throat of at least moderate pain intensity
- Exclusion Criteria:
- • - History of hypersensitivity to any of the study drugs and listed excipients or to drugs of similar chemical classes
- • Evidence of mouth breathing or severe coughing
- • Evidence of overt oropharyngeal bacterial or fungal infection or evidence of lower respirator tract infection
- • Severe renal, liver or cardiac impairment
- • Severe lung disease
About Novartis
Novartis is a global healthcare company based in Switzerland, dedicated to reimagining medicine to improve and extend people's lives. With a strong focus on innovative pharmaceuticals, Novartis engages in the research, development, and commercialization of a wide range of therapies across various therapeutic areas, including oncology, cardiology, immunology, and neuroscience. The company is committed to advancing clinical research through rigorous trials that prioritize patient safety and efficacy, aiming to deliver groundbreaking treatments and solutions that address unmet medical needs worldwide. Novartis's commitment to innovation and collaboration positions it at the forefront of the biopharmaceutical industry, driving advancements that enhance patient care and health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Erfurt, Germany
Patients applied
Trial Officials
Investigator
Principal Investigator
SocraTec R&D GmbH
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials